English	French	Notes	Complete/Exclude
24. REGIONAL NODES EXAMINED.........: 			
25. REGIONAL NODES POSITIVE.........: 			
26. EXTRANODAL EXTENSION............: 			
    SATELLITE NODULES OF SKIN OR SUBCUTANEOUS TISSUE			
28. NUMBER OF SATELLITE NODULES.....: 			
29. LOCATION OF IN-TRANSIT NODULES..: 			
31. CLARK'S LEVEL OF INVASION.......: 			
32. ANGIOLYMPHATIC INVASION.........: 			
33. PERINEURAL INVASION.............: 			
34. GENERAL SUMMARY STAGE...........: 			
35. AJCC CLINICAL STAGE (cTNM):			
     AJCC STAGE.....................: 			
37. CLINICALLY AMELANOTIC...........: 			
38. AJCC PATHOLOGIC STAGE (pTNM):			
39. STAGED BY:			
     CLINICAL STAGE.................: 			
     PATHOLOGIC STAGE...............: 			
40. PROTOCOL ELIGIBILITY STATUS.....: 			
41. PROTOCOL PARTICIPATION..........: 			
42. DATE OF FIRST COURSE TREATMENT..: 			
43. DATE OF NON CA-DIRECTED SURGERY.: 			
44. NON CANCER-DIRECTED SURGERY.....: 			
45. TYPE OF BIOSPY..................: 			
46. DATE OF CANCER-DIRECTED SURGERY.: 			
47. SURGICAL APPROACH...............: 			
48. SURGERY OF PRIMARY SITE.........: 			
49. SURGICAL MARGINS................: 			
50. DISTANCE FROM TUMOR TO EDGE OF			
51. SCOPE OF LYMPH NODE SURGERY.....: 			
52. NUMBER OF LYMPH NODES REMOVED...: 			
53. SURGERY OF OTHER REGIONAL SITE(S), DISTANT SITE(S),			
    OR DISTANT LYMPH NODE(S)........: 			
55. SURGICAL CLOSURE................: 			
56. REASON FOR NO SURGERY...........: 			
57. PRE-OP LYMPHOSCINTIGRAPHY.......: 			
58. SENTINEL NODES DETECTED BY......: 			
59. SENTINEL NODE BIOPSY............: 			
60. SENTINEL NODES EXAMINED.........: 			
61. SENTINEL NODES POSITIVE.........: 			
62. HOW WAS SENTINEL NODE			
    PATHOLOGICALLY EXAMINED.........: 			
63. IF SENTINEL NODE(S) POSITIVE:			
      WAS COMPLETE LYMPH NODE			
      DISSECTION PERFORMED..........: 			
      NUMBER OF BASINS DETECTED.....: 			
      NUMBER OF BASINS POSITIVE.....: 			
64. DATE RADIATION STARTED..........: 			
65. RADIATION THERAPY...............: 			
66. REASON FOR NO RADIATION ........: 			
67. DATE CHEMOTHERAPY STARTED.......: 			
69. INTRAVENOUS THERAPY.............: 			
70. DATE HORMONE THERAPY STARTED....: 			
71. HORMONE THERAPY.................: 			
    IMMUNOTHERAPY THERAPY			
72. DATE IMMUNOTHERAPY STARTED......: 			
74. IMMUNOTHERAPEUTIC AGENTS ADMINISTERED:			
     VACCINE THERAPY................: 			
     GENE THERAPY...................: 			
     COLONY STIMULATING FACTORS.....: 			
     OTHER GIVEN, TYPE UNKNOWN......: 			
    OTHER THERAPY			
75. DATE OTHER TREATMENT STARTED....: 			
76. OTHER TREATMENT.................: 			
77. DATE OF FIRST RECURRENCE........: 			
78. TYPE OF FIRST RECURRENCE........: 			
79. OTHER TYPE OF FIRST RECURRENCE..: 			
80. DATE OF LAST CONTACT OR DEATH...: 			
81. VITAL STATUS....................: 			
82. CANCER STATUS...................: 			
TABLE VII - OTHER INFORMATION			
83. COMPLETED BY....................: 			
84. REVIEWED BY CANCER COMMITTEE....: 			
The BEHAVIOR code is not 3 (malignant).			
8:Print Non-Hodgkin's Lymphoma PCE			
Patient Care Evaluation Study of Non-Hodgkin's Lymphoma			
AGE AT DIAGNOSIS			
PERSONAL HISTORY OF ANY CANCER			
PRE-EXISTING CONDITIONS			
PREVIOUS CHEMOTHERAPY/RADIATION THERAPY			
AIDS RISK CATEGORY			
AIDS RISK CATEGOR			
AGE AT DIAGNOSIS.....................: 			
313  OTHER CANCER.......................			
PERSONAL HISTORY OF ANY CANCER:			
803  1ST PRIMARY SITE...................			
803  1ST PRIMARY SITE...................//			
804  1ST PRIMARY HISTOLOGY..............			
804  1ST PRIMARY HISTOLOGY..............//			
805  2ND PRIMARY SITE...................			
805  2ND PRIMARY SITE...................//			
806  2ND PRIMARY HISTOLOGY..............			
806  2ND PRIMARY HISTOLOGY..............//			
PRE-EXISTING CONDITIONS:			
807  ORGAN TRANSPLANT...................			
808  HIV POSITIVE.......................			
809  CROHN'S DISEASE/ULCERATIVE COLITIS.			
811  SYSTEMIC LUPUS ERYTHEMATOSUS.......			
812  RHEUMATOID ARTHRITIS/SJOGREN'S SYN.			
813  PNEUMOCYSTIS CARINII...............			
814  CMV INFECTION......................			
816  MYCOBACTERIUM AVIUM................			
817  OTHER PARASITIC INFECTIONS.........			
818  OTHER CONGENTIAL DISEASES..........			
819  OPPORTUNISTIC DISEASE (W/I 2 YEARS)			
PREVIOUS CHEMOTHERAPY/RADIATION THERAPY:			
821  RADIATION THERAPY..................			
822AIDS RISK CATEGORY...................			
DIAGNOSTIC WORKUP			
RESULTS OF LABORATORY TESTS			
ADDITIONAL TESTS			
REVIEW OF PATHOLOGY/OTH INST			
DIAGNOSTIC BIOPSIES			
SYSTEMIC SYMPTOMS			
DIAGNOSTIC TEST SPECIFICALLY RELATED TO HIV DISEASE			
HIV VIRAL LOADS			
SPECIFIC HISTOLOGIC INFORMATION			
CELL TYPE OF LYMPHOMA			
PATIENT STATUS AT DIAGNOSIS			
CLASS OF CLASS..............: 			
26DIAGNOSTIC CONFIRMATION.....			
DIAGNOSTIC WORKUP:			
823  CT SCAN OF BRAIN..........			
506  CT SCAN OF CHEST..........			
824  CT SCAN OF ABDOMEN/PELVIS.			
825  MRI OF BRAIN..............			
826  MRI OF CHEST..............			
827  MRI OF ABDOMEN/PELVIS.....			
504  BONE SCAN.................			
828  GALLIUM SCAN..............			
829  PET SCAN..................			
830  LUMBAR PUNCTURE...........			
RESULTS OF LABORATORY TESTS:			
832  WHITE COUNT...............			
833  PLATELET COUNT............			
834  LACTIC DEHYDROGENASE (LDH)			
835  LIVER FUNCTION STUDIES....			
836  TOTAL PROTEIN/ALBUMIN.....			
ADDITIONAL TESTS:			
516  TUMOR SURFACE MARKER......			
514  CYTOGENETIC TESTING.......			
837  GENE REARRANGEMENTS.......			
838REVIEW OF PATHOLOGY/OTH INST			
DIAGNOSTIC BIOPSIES:			
839  LYMPH NODE................			
840  BONE MARROW...............			
841  CSF CYTOLOGY..............			
842  OTHER SITE................			
843SYSTEMIC SYMPTOMS...........			
DIAGNOSTIC TESTS SPECIFICALLY RELATED TO HIV DISEASE:			
845  HIV VIRAL LOADS...........			
DATE OF INITIAL DIAGNOSIS...: 			
PRIMARY SITE................: 			
HISTOLOGY/BEHAVIOR CODE.....: 			
846SPECIFIC HISTOLOGIC INFO....			
847CELL TYPE OF LYMPHOMA.......			
848PATIENT STATUS AT DIAGNOSIS.			
AJCC CLINICAL STAGE GROUP			
CLINICALLY STAGED BY			
AJCC PATHOLOGIC STAGE GROUP			
PATHOLOGICALLY STAGED BY			
TYPE OF STAGING SYSTEM (PEDIATRIC)			
PEDIATRIC STAGE			
STAGED BY (PEDIATRIC STAGE)			
EXTRANODAL SITES			
AJCC CLINICAL STAGE GROUP......: 			
19CLINICALLY STAGED BY...........			
AJCC PATHOLOGIC STAGE GROUP ...: 			
89PATHOLOGICALLY STAGED BY.......			
849TYPE OF STAGING SYS (PEDIATRIC)			
850PEDIATRIC STAGE................			
851STAGED BY (PEDIATRIC STAGE)....			
EXTRANODAL SITES:			
852  EXTRANODAL SITE 1............			
853  EXTRANODAL SITE 2............			
854  EXTRANODAL SITE 3............			
DATE OF FIRST COURSE OF TREATMENT			
SYSTEMIC CHEMOTHERAPY			
INTRATHECAL CHEMOTHERAPY			
DATE OF FIRST COURSE OF TREATMENT.: 			
  EXTRANODAL SURGERY SITE.........: None			
  EXTRANODAL SURGICAL PROCEDURE...: 00 No additional surgical procedures			
855  EXTRANODAL SURGERY SITE.........			
856  EXTRANODAL SURGICAL PROCEDURE...			
  RADIATION DATE..................: 			
  IRRADIATED FIELDS:			
    LYMPH NODES ABOVE DIAPHRAGM...: Not irradiated			
    LYMPH NODES BELOW DIAPHRAGM...: Not irradiated			
    BRAIN.........................: Not irradiated			
    OTHER EXTRANODAL SITE(S)......: Not irradiated			
    TOTAL BODY....................: Not irradiated			
  RADIATION/CHEMOTHERAPY SEQUENCE.: NA, no radiation and/or no chemo given			
    LYMPH NODES ABOVE DIAPHRAGM...: NA, unknown if radiation therapy given			
    LYMPH NODES BELOW DIAPHRAGM...: NA, unknown if radiation therapy given			
    BRAIN.........................: NA, unknown if radiation therapy given			
    OTHER EXTRANODAL SITE(S)......: NA, unknown if radiation therapy given			
    TOTAL BODY....................: NA, unknown if radiation therapy given			
  RADIATION/CHEMOTHERAPY SEQUENCE.: Unknown if radiation and/or chemo given			
857    LYMPH NODES ABOVE DIAPHRAGM...			
858    LYMPH NODES BELOW DIAPHRAGM...			
860    OTHER EXTRANODAL SITE(S)......			
861    TOTAL BODY....................			
862  RADIATION/CHEMOTHERAPY SEQUENCE.			
864  SYSTEMIC CHEMOTHERAPY...........			
  SYSTEMIC CHEMOTHERAPY DATE......: 00/00/0000			
  NUMBER OF PLANNED CYCLES........: NA			
  AGENT ADMINISTERED DURING SYSTEMIC CHEMOTHERAPY:			
    SINGLE-AGENT CHEMOTHERAPY:			
      CHLORAMBUCIL.....: NA   DOXORUBICIN......: NA			
      CYCLOPHOSPHAMIDE.: NA   FLUDARABINE......: NA			
    COMBINATION CHEMOTHERAPY:			
      CVP..............: NA   PRO-MACE-Cyta BOM: NA			
      COMLA............: NA   OTHER............: NA			
    HIGH DOSE W STEM CELL RESCUE..: No			
  NUMBER OF PLANNED CYCLES........: Unknown if chemotherapy given			
      CHLORAMBUCIL.....: Unknown if given   DOXORUBICIN......: Unknown if given			
      CYCLOPHOSPHAMIDE.: Unknown if given   FLUDARABINE......: Unknown if given			
      CHOP.............: Unknown if given   M-BACOD..........: Unknown if given			
      CVP..............: Unknown if given   PRO-MACE-Cyta BOM: Unknown if given			
      COMLA............: Unknown if given   OTHER............: Unknown if given			
      MACOP-B..........: Unknown if given			
    HIGH DOSE W STEM CELL RESCUE..: Unknown if given			
865  SYSTEMIC CHEMOTHERAPY DATE......			
866  NUMBER OF PLANNED CYCLES........			
876      PRO-MACE-Cyta BOM...........			
878  HIGH DOSE W STEM CELL RESCUE....			
879  INTRATHECAL CHEMOTHERAPY........			
  PURPOSE.........................: NA, not administered			
  PURPOSE.........................: Unknown if administered			
883  MONOCLONAL ANTIBODIES...........			
884  VACCINE THERAPY.................			
OTHER TYPE OF FIRST RECURRENCE			
71.4OTHER TYPE OF FIRST RECURRENCE			
 1. INSTITUTION ID NUMBER...........: H6			
 6. AGE AT DIAGNOSIS................: 			
 8. SPANISH ORIGIN..................: 			
10. PRIMARY PAYER AT DIAGNOSIS......: 			
11. FAMILY HISTORY OF CANCER:			
      OTHER CANCER..................: 			
12. PERSONAL HISTORY OF ANY CANCER:			
      1ST PRIMARY SITE..............: 			
      1ST PRIMARY HISTOLOGY.........: 			
      2ND PRIMARY SITE..............: 			
      2ND PRIMARY HISTOLOGY.........: 			
13. PRE-EXISTING CONDITIONS:			
      ORGAN TRANSPLANT..............: 			
      HIV POSITIVE..................: 			
      CROHN'S DIS/ULCERATIVE COLITIS: 			
      SYSTEMIC LUPUS ERYTHEMATOSUS..: 			
      RHEUMATOID ARTHRITIS/SJOGREN'S: 			
      PNEUMOCYSTIS CARINII..........: 			
      CMV INFECTION.................: 			
      MYCOBACTERIUM AVIUM...........: 			
      OTHER PARASITIC INFECTIONS....: 			
      OTHER CONGENITAL DISEASES.....: 			
      OPPORTUNISTIC DISEASE.........: 			
14. PREVIOUS CHEMOTHERAPY/RADIATION THERAPY:			
      RADIATION THERAPY.............: 			
15. AIDS RISK CATEGORY..............: 			
Print Non-Hodgkin's Lymphoma PCE			
PCE Study of Non-Hodgkin's Lymphoma			
16. CLASS OF CASE...................: 			
17. DIAGNOSTIC CONFIRMATION.........: 			
18. DIAGNOSTIC WORKUP:			
      CT SCAN OF BRAIN..............: 			
      CT SCAN OF CHEST..............: 			
      CT SCAN OF ABDOMEN/PELVIS.....: 			
      MRI OF BRAIN..................: 			
      MRI OF CHEST..................: 			
      MRI OF ABDOMEN/PELVIS.........: 			
      BONE SCAN.....................: 			
      GALLIUM SCAN..................: 			
      PET SCAN......................: 			
      LUMBAR PUNCTURE...............: 			
19. RESULTS OF LABORATORY TESTS:			
      WHITE COUNT...................: 			
      PLATELET COUNT................: 			
      LACTIC DEHYDROGENASE (LDH)....: 			
      LIVER FUNCTION STUDIES........: 			
      TOTAL PROTEIN/ALBUMIN.........: 			
20. ADDITIONAL TESTS:			
      TUMOR SURFACE MARKER..........: 			
      CYTOGENETIC TESTING...........: 			
      GENE REARRANGEMENTS...........: 			
21. REVIEW OF PATHOLOGY/OTH INST....: 			
22. DIAGNOSTIC BIOPSIES:			
      LYMPH NODE....................: 			
      BONE MARROW...................: 			
      CSF CYTOLOGY..................: 			
      OTHER SITE....................: 			
23. SYSTEMIC SYSTEMS................: 			
24. DIAGNOSTIC TESTS SPECIFICALLY RELATED TO HIV DISEASE:			
      HIV VIRAL LOADS...............: 			
25. DATE OF INITIAL DIAGNOSIS.......: 			
26. PRIMARY SITE....................: 			
27. HISTOLOGY/29. BEHAVIOR CODE.....: 			
28. SPECIFIC HISTOLOGIC INFO........: 			
30. CELL TYPE OF LYMPHOMA...........: 			
31. PATIENT STATUS OF DIAGNOSIS.....: 			
32. AJCC CLINICAL STAGE GROUP.......: 			
33. CLINICALLY STAGED BY............: 			
34. AJCC PATHOLOGIC STAGE GROUP.....: 			
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################	
####################	####################	####################